Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study

AIMS: To demonstrate non-inferiority of ranibizumab treat-and-extend (T&E) with/without laser to ranibizumab pro re nata (PRN) for best-corrected visual acuity (BCVA) in patients with diabetic macular oedema (DMO). METHODS: A 24-month single-masked study with patients randomised 1:1:1 to T&E...

Descripción completa

Detalles Bibliográficos
Autores principales: Prünte, Christian, Fajnkuchen, Franck, Mahmood, Sajjad, Ricci, Federico, Hatz, Katja, Studnička, Jan, Bezlyak, Vladimir, Parikh, Soumil, Stubbings, William John, Wenzel, Andreas, Figueira, João
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893084/
https://www.ncbi.nlm.nih.gov/pubmed/26453639
http://dx.doi.org/10.1136/bjophthalmol-2015-307249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893084/
https://www.ncbi.nlm.nih.gov/pubmed/26453639
http://dx.doi.org/10.1136/bjophthalmol-2015-307249

Ejemplares similares